Skip to main content

Added value of interferon-gamma release assays in screening for tuberculous infection in the Netherlands

Buy Article:

$34.78 + tax (Refund Policy)

BACKGROUND: Interferon-gamma release assays (IGRAs) are reported to be more specific for the diagnosis of latent tuberculous infection (LTBI) than the tuberculin skin test (TST). The two-step procedure, TST followed by an IGRA, is reported to be cost-effective in high-income countries, but it requires more financial resources.

OBJECTIVE: To assess the added value of IGRA compared to TST alone in the Netherlands.

METHODS: Test results and background data on persons tested with an IGRA were recorded by the Public Municipal Health Services in a web-based database. The number of persons diagnosed with LTBI using different screening algorithms was calculated.

RESULTS: In those tested with an IGRA, at least 60% of persons who would have been diagnosed with LTBI based on TST alone had a negative IGRA. Among those with a TST reaction below the cut-off for the diagnosis of LTBI, 13% had a positive IGRA. For 41% of persons tested with an IGRA after TST, the IGRA influenced whether or not an LTBI diagnosis would be made.

CONCLUSION: With the IGRA as reference standard, a high proportion of persons in low-prevalence settings are treated unnecessarily for LTBI if tested with TST alone, while a small proportion eligible for preventive treatment are missed. Incremental costs of the two-step strategy seem to be balanced by the improved targeting of preventive treatment.

Keywords: cost-effectiveness; interferon-gamma release assay; latent tuberculous infection; public health resources

Document Type: Research Article

Affiliations: 1: KNCV Tuberculosis Foundation, The Hague, The Netherlands 2: KNCV Tuberculosis Foundation, The Hague, The Netherlands 3: Public Health Service Rotterdam Rijnmond, Rotterdam, The Netherlands 4: GGD Twente, Enschede, The Netherlands 5: GGD Brabant Zuidoost, Eindhoven, The Netherlands 6: GGD Zuid Limburg, Heerlen, The Netherlands 7: GGD Den Haag, Den Haag, The Netherlands 8: Public Health Services Amsterdam, Amsterdam, The Netherlands

Publication date: 01 April 2014

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.

    The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content